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Among adult humans, females reportedly have more severe morbidity than males following exposure 
to novel strains of influenza A viruses (e.g., pandemic or avian influenza viruses). Females also have 
higher antibody titers to influenza vaccine antigens than their male counterparts. Male-female 
differences in influenza virus infection and vaccine responses can be recapitulated in mice suggesting 
that biological differences between the sexes may be involved. Toll-like receptor 7 (TLR7) is a 
pattern recognition receptor for single stranded RNA viruses and plays a role in the innate detection 
and activation of inflammatory signaling in plasmacytoid dendritic cells (pDCs).  TLR7 also exists in 
B cells and signaling in B cells is important for antibody response, including isotype switching. TLR7 
is located on the X chromosome and was recently shown to escape X inactivation in B cells. Whether 
females have greater dependence than males on TLR7-dependent signaling during influenza virus 
infection or vaccination has not been reported and was tested in the current thesis. Adult male and 
female wild-type and Tlr7 deficient mice on a C57BL/6NJ background were infected with an 
influenza A virus (i.e., mouse adapted A/CA/09 H1N1 [2009 H1N1]) and monitored for virus 
replication kinetics, pulmonary inflammation, and morbidity to characterize possible sex differences 
in influenza pathogenesis in the absence of TLR7-depedent signaling. Among wild-type mice, females 
experienced greater morbidity, cleared virus faster, but had similar levels of pulmonary inflammation 
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as compared with males. Female-biased morbidity, but not virus clearance, still occurred among Tlr7 
deficient mice, suggesting that elimination of TLR7-depedent signaling did not alter sex differences 
in the pathogenesis of influenza. Next adult male and female wild-type and Tlr7 deficient mice 
received an inactivated 2009 H1N1 vaccine using a prime-boost strategy. Serum samples were 
collected at several time-points to evaluate antibody responses, and animals were challenged with a 
2009 H1N1 drift variant virus to evaluate protection following vaccination. Among wild-type mice, 
females produced greater neutralizing, total IgG, and IgG2c titers that had a greater avidity index 
than males. In the absence of Tlr7, the sex difference in titers of neutralizing antibody, total IgG 
antibody, and IgG2c antibody titers as well as the avidity index following vaccination were 
eliminated, primarily due to a significant decline in antibody responses from Tlr7-/- females. 
Following virus challenge, wild-type females cleared virus from their lungs faster than males and this 
female-biased control of virus replication was eliminated in the absence of Tlr7. Taken together our 
results demonstrate that Tlr7 promotes a more robust vaccine-induced antibody response in females 
and the absence of Tlr7 eliminates the sex-specific difference in viral clearance following challenge. 
Influenza vaccination reportedly results in sex-specific antibody responses following vaccination and 
our data suggests this may be due to TLR7. Greater consideration should be given to sex-dependent 
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Host Recognition of Viruses 
I. Toll-like Receptors 
Toll-like receptors (TLR) are arguably the most fundamental immune receptors in our body, in spite 
of their recent discovery in 1996 (Lemaitre, Nicolas, Michaut, Reichhart, & Hoffmann, 1996). As a 
core part of our inherited resistance to disease, TLR proteins allow mammals to detect invading 
microbes and initiate an appropriate response (Beutler, 2004). Most of the phenomena that occur in 
the course of infection are orchestrated by TLRs or other pattern recognition receptors (PRRs) found 
on or inside our cells (Beutler, 2004). Despite the extreme chemical complexity of microbial stimuli, 
only a handful of TLRs and two adaptor proteins are needed for the detection of most microbes 
(Beutler, 2004). This is possible because each TLR recognizes a different evolutionarily conserved 
pathogen-associated molecular pattern (PAMP) that is both semi-specific to the microbial world and 
invariant among entire classes of pathogens (Iwasaki & Medzhitov, 2004; Janeway Jr., 1998). All 
together the TLRs recognize the molecular patterns of almost all bacteria, fungi, and viruses that infect 
mammals, including humans(Murphy, Travers, Walport, & Janeway, 2012).  
Although the of ratio of TLRs to microbial molecules is extremely small (10:>1,000), the 
secondary/tertiary events triggered by TLR activation are highly specific with a ratio closer to 1:1 
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(Beutler, 2004). This complexity is conferred through the type of cell expressing the TLR, the level of 
TLR expression, the combination of PRRs activated, the timing of TLR activation, the hundreds of 
different effectors responsive to TLR signaling, and recent evidence suggests the sex of the host (Liu 
& Ding, 2016; Souyris et al., 2018). Following stimulation by microbes, TLRs transduce a signal 
through adaptor proteins myeloid-differentiation primary response gene88 (MyD88) or TIR-domain-
containing adapter-inducing interferon-β (TRIF). This signal is propagated through serine kinases, 
ultimately resulting in the activation of a specific set of transcription factors, most notably NF-kB, 
interferon regulatory factor (IRF) family members, and mitogen-activated protein kinase (MAPK) 
(Beutler, 2004). 
While bacteria, fungi, and parasites are recognized by cell-surface TLRs that target multiple 
molecules associated with their structure and metabolism, viruses are primary recognized by their 
nucleic acids alone. Thus, TLRs that recognize nucleic acids play a critical role during viral infection. 
In humans and mice these TLRs include TLR3 which responds to dsRNA, TLR9 which responds to 
dsDNA, and TLR7 and TLR8 (humans only) which respond to purine-rich ssRNA. The biological 
relevance of intracellular TLRs can be inferred from their evolution under strong purifying selection. 
In human populations, intracellular TLRs have extremely low rates of nonsynonymous and stop 
mutations not seen among cell-surface TLRs. Worldwide, TLR7 and TLR9 have the least genetic 
diversity in human populations. This is likely because intracellular TLRs play a specialized, non-
redundant role in host survival, either via protective immunity against viral infections (present or past), 
additional involvement in other non-immunity related important biological processes, or both (Barreiro 
et al., 2009; Souyris et al., 2018). Understanding the role of TLRs in mediating the immune response 
to viruses, such as influenza A viruses (IAVs), particularly in the context of vaccination, therefore 
continues to be an important area of study and will be the focus of this thesis.  
II. TLR7, Plasmacytoid Dendritic Cells, and Type I Interferons 
During an infection with IAV, TLR7 is one of multiple PRRs used to recognize unique features 
associated with the virus. PRRs that recognize influenza viruses can be organized into three distinct 
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families: 1) the TLRs, including TLR3, TLR7, and TLR8; 2) the retinoic acid-inducible gene I (RIG-I); 
and 3) the NOD-like receptor family member NOD-, LRR- and pyrin domain-containing 3 (NLRP3) 
(Iwasaki & Pillai, 2014; Pang & Iwasaki, 2012). They can also be categorized by whether their viral 
sensing is cell-intrinsic, mediated by infected cells, or cell-extrinsic, mediated by uninfected cells. RIG-
I and NLRP3 sense IAV through cell-intrinsic recognition when viral nucleic acids or viral damage is 
detected in the cytosol. They are ubiquitously expressed in the cytosol of immune and non-immune 
cells. Alternatively, TLR3 and TLR7 generally sense IAV through cell-extrinsic recognition when they 
detect viral nucleic acids in endosomes. These PRRs tend to be expressed in sentinel cells such as 
macrophages and dendritic cells (DCs) where they are used to sample phagocytosed material for the 
presence of viral nucleic acids. (Iwasaki & Medzhitov, 2010; Pang & Iwasaki, 2012; Stetson, 2009).  
Following the infection of non-immune cells, primarily respiratory epithelial cells, with IAV, 
RIG-I is activated and following the detection of IAV by sentinel immune cells, TLRs are activated. 
Activation of TLRs and RIG-I triggers a signaling cascade that culminates in the production of pro-
inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) through 
nuclear factor κB (NF-κB), and the production of Type I interferons (IFN) through IRF3 and/or IRF7 
activation. During a viral infection (e.g., with IAV), the predominant effectors are IFNs. IFNs drive 
the expression of over 300 genes, collectively known as IFN-stimulated genes (ISGs) which cooperate 
to control virus infection and spread (Katze, M.G., He, Y. & Gale, M., 2002; Lund et al., 2004; Pang 
& Iwasaki, 2012). Type I IFNS and ISGs induce antiviral protection by establishing an antiviral state 
in neighboring cells and by activating key cells in the adaptive immune responses for efficient viral 
clearance (Stetson & Medzhitov, 2006; Takeuchi & Akira, 2007).  
The primary producers of type I IFNs are plasmacytoid dendritic cells (pDCs) which produce 
from a hundred to a thousand times more IFN-α than other cell types (Hoffmann, Schneider, & Rice, 
2015; Siegal, 1999). This is thought to be possible because pDCs express high levels of TLR7 
(Berghofer et al., 2006; Kadowaki & Liu, 2002). In pDCs, which do not express TLR3 in mice or 
humans, activation of TLR7 allows for the recruitment of IRF7 and the induction of robust levels of 
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type I IFNs (Pang & Iwasaki, 2012). TLR7 signaling in pDCs also upregulates cytosolic sensors of viral 
products, such as RIG-I, further amplifying the induction of the antiviral state (S. S. Diebold, 2004; 
Sandra S Diebold et al., 2003).  One advantage for the immune system of using this strategy against 
viral infections is that TLR7 is activated in a cell-extrinsic manner and thus not directly inhibited by 
viral proteins that antagonize PRRs like RIG-I,  associated with type I IFN induction in infected cells 
(Stetson, 2009).  
Although the role of TLR7 in pDCs appears to be unique, mouse models have shown that the 
TLR7 and the RIG-I pathways are redundant during viral infection. Both TLR7 and RIG-I pathways 
compensate for the loss of the other upon high-dose IAV challenge, for example (Pang, Pillai, & 
Iwasaki, 2013). A systematic comparison of the genes activated by TLRs and RIG-I-like receptors 
revealed that a small portion of genes are uniquely turned on by TLRs (Iwasaki & Pillai, 2014; Negishi 
et al., 2012). Thus, the redundancy between TLR7 and RIG-I in the innate immune response to IAV 
infection may be specific to the extent of viral burden. Furthermore, while the roles of TLR7 and RIG-
I may be redundant in the innate immune response to IAV, their roles in the adaptive immune response 
which ultimately results in viral clearance and recovery are very distinct. Specifically, antibody responses 
during IAV mainly rely on TLR7 expressed by B cells (Heer et al., 2007; Jeisy-Scott et al., 2012).  
III. TLR7 in B cells  
Triggered by the innate immune response during the early phase of IAV infection, the adaptive immune 
response uses two different effector mechanisms to clear the infection and allow for recovery. These 
two effector mechanisms are the production of antibodies by B cells which bind and block viral spread, 
and the activation of cytotoxic cells such as CD8+ T cells which eliminate virus-infected cells. The 
initiation of both mechanisms is dependent on specific PRRs expressed in antigen-presenting cells 
(APCs) and B cells. Human and murine B cells express several TLRs; the expression of TLR7 in 
immune cells at steady state, however, is close to its highest in B cells (Bekeredjian-Ding & Jego, 2009; 
Hua & Hou, 2013). The detection of non-replicating, single stranded IAV nucleic acid via TLR7 by B 
cells induces the production of IgG2c antibodies and CD4+ T cell responses (Koyama et al., 2007; 
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Lopez et al., 2004; Thomas et al., 2009). The production of IgG2c antibodies is critical for lasting 
immunity and the role of TLR7 in eliciting such responses in B cells has become a major area of focus 
in vaccine research.   
Whole inactivated vaccines such as those used for seasonal IAV vaccination, contain viral genomic 
RNA and rely heavily on TLR7 engagement to elicit adaptive immunity (Jeisy-Scott et al., 2012). When 
Tlr7 deficient mice were immunized with split inactivated IAV, they had significantly reduced antibody 
titers. Furthermore, following challenge, immunized Tlr7 deficient mice were less able to control IAV 
replication, with lung viral titers 100-fold higher than immunized control mice (Jeisy-Scott et al., 2012). 
Another study obtained similar results, with Tlr7 deficient mice being unprotected against a lethal dose 
of IAV following two immunizations with inactivated virus (Koyama et al., 2007). Additionally, an 
analysis of serum IgG titer (IgG2c, in particular) against “immunodominant” HA Ag was found to be 
significantly reduced in immunized Tlr7 deficient mice as compared to immunized controls just prior 
to challenge.  
The mechanism by which TLR7 confers antibody-mediated protection following vaccination 
appears to be complex and involve both direct and indirect signaling pathways with B cells. An in vitro 
study of B cells found that TLR7 induces isotype switching indirectly through the activation of T helper 
cells and pDC which both act on B cells, and directly through TLR7 signaling within B cells (Heer et 
al., 2007; Koyama et al., 2007). When B cells were stimulated with TLR7 or CD4 T cell ligands directly, 
they proliferated and produced IgG1, but the production of IgG2c required both of these signals 
together with pDC production of IFNα (Heer et al., 2007). IgG2c (sometimes referred to as IgG2a) is 
the major isotype produced during a viral infection and the most efficient in antibody-mediated 
protection (Coutelier, 1988; Markine-Goriaynoff & Coutelier, 2002; Rubtsova, Rubtsov, van Dyk, 
Kappler, & Marrack, 2013; Schmitz et al., 2012). In addition to TLR7, T-bet expression in B cells have 
been shown to be critical for isotype switching to IgG2c during viral infection (Deng et al., 2016; Gerth, 
Lin, & Peng, 2003; Rubtsova et al., 2013; Snapper & Paul, 1987). Furthermore, an in vitro study found 
the combination of a TLR and BCR agonist induced the highest expression of T-bet in splenic B cells 
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purified from mice (Rubtsova et al., 2013). Together these data suggest that TLR7 in cells of the innate 
and adaptive immune system may work together synergistically to induce class-switching to IgG2c in 
response to viral infection.  
Sex influences innate and adaptive immune responses 
In addition to its function in B cells, TLR7 is also unique in its location on the X chromosome 
(Christensen et al., 2006). Although the mechanism of X chromosome inactivation (XIC) in placental 
mammals was considered extremely stable in adults, recent studies have shown some genes on the X 
chromosome that are outside the pseudoautosomal regions shared with the Y chromosome, escape 
XIC. Studies have observed 15% of X-chromosomal genes in human primary fibroblasts and 3.3% in 
mice kidney cells, escape X inactivation (Carrel & Willard, 2005; Yang et al., 2010). Most recently a 
study demonstrated that TLR7 is transcribed on both X chromosomes in a large proportion of the 
pDCs, B cells, and monocytes from normal women. The researchers also found that in B cells this 
biallelic expression of TLR7 led to increased TLR7 gene products and enhanced B cell responses to 
TLR7 engagement (Souyris et al., 2018). Our lab has been able to replicate these results in the context 
of vaccinated C57BL/6 mice with female B cells expressing higher levels of TLR7 mRNA 28 days 
following vaccination as compared to vaccinated males (Dr. Ashley Fink, unpublished data). 
The recent observation of sex differences in TLR7 expression by immune cells is coupled with 
an increasing number of sex difference observations in viral disease pathogenesis and vaccine response 
among humans. Generally human studies have shown that females tend to generate a stronger innate 
and adaptive immune response compared to males. Depending on whether a strong immune response 
is beneficial or damaging for host survival, females suffer more or less than men (Klein & Roberts, 
2015). In the context of influenza infection, females of reproductive age have been shown to suffer 
more than their male counterparts. During the 2009 H1N1 pandemic (pdm), females were more likely 
than males to develop severe disease. Interestingly the male-female differences in incidence, severity 
and mortality rates of 2009 H1N1pdm infection varied by age at infection (CDC, n.d.; Peretz, Hall, & 
Klein, 2015). Regardless of hospitalization status, males less than 19 years of age had a higher risk of 
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laboratory confirmed H1N1pdm than females. But, among adults aged 18-64 years, both hospitalized 
and not hospitalized, women had a higher risk of laboratory confirmed H1N1pdm  (Jacobs et al., 2012; 
Peretz et al., 2015). 
In addition to influenza pathogenesis, sex differences have also been observed in response to 
influenza vaccination among humans. Following receipt of seasonal influenza virus trivalent inactivated 
vaccine (TIV), women have a higher hemagglutination (HAI) antibody titer than males (Peretz et al., 
2015). This trend is seen with different assays, across multiple IAV vaccine strains, and in both young 
(18-64 years of age) and older (65+ years of age) females. Adult human females given a half dose of 
TIV had an equivalent or higher neutralizing antibody response compared to adult men given a full 
dose (Engler, 2008). Even when comparing males and females of the same age, females had a greater 
absolute change in neutralizing antibody titers against H3N2 and influenza B antigens following TIV 
than males (Furman et al., 2014; Peretz et al., 2015). This increased antibody response in females was 
also associated with higher levels of proinflammatory molecules and more adverse reactions following 
vaccination (Furman et al., 2014).  
IV. Animal models of influenza infection and vaccination 
Understanding the cause and effect of sex differences in the human population is difficult for ethical 
reasons, however animal models offer a unique opportunity for expanding our knowledge when sex is 
considered as a biological variable. Unfortunately, many preclinical studies only use one sex and/or do 
not state the sex of their animals (Potluri, Engle, Fink, vom Steeg, & Klein, 2018). This has had severe 
consequences on clinical trial participants and more generally on our ability to leverage beneficial sex 
differences to develop new treatments.    
When sex has been considered as a biological variable in the context of influenza infection, 
mouse models have enabled researchers to understand how sex differences in the immune response 
lead to more severe disease in females. Specifically, mouse models have shown female mice have an 
increased inflammatory response to infection and that this leads to increased pathology. Within the 
first week following infection with H1N1, female C57/BL6 mice show a greater induction of cytokines 
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and chemokines in their lungs than males (Peretz, Hall, & Klein, 2015). Additionally, this trend has 
been seen across different virus and mouse strains. When adult BALB/c mice are infected with H3N1 
IAV, females develop greater lung hyperresponsiveness to methacholine challenge and produce more 
CCL2, an inflammatory cytokine, than males (Boylen, Sly, Zosky, & Larcombe, 2011; Peretz et al., 
2015).  
Animal models have also provided new insight into the differential efficacy of vaccines in each 
sex. Similar to humans, following vaccination with ma H1N1 or H3N2, female mice of reproductive 
ages mount higher neutralizing and total antibody responses than males (Lorenzo et al., 2011; Peretz 
et al., 2015). Furthermore when immunized mice are challenged with a lethal dose of a different IAV 
strain, males experience greater morbidity and have higher viral titers in their lungs (Lorenzo et al., 
2011). In response to vaccines female mice mount higher anti-IAV antibodies and have better cross 
protection against IAV (Lorenzo et al., 2011).  Interestingly, both male and female mice were equally 
protected when challenged with a lethal dose of the same virus against which they were immunized, 
suggesting sex differences in the quality of antibody are complex and require more research.  
Hypotheses and aims 
Despite strong evidence of sex differences in influenza vacation and the emerging role of TLR7 in the 
immune response to vaccination, TLR7 has yet to be studied in the context of sex differences in 
response to influenza infection or vaccination. Therefore, the primary aim of this study is to fill this 
critical knowledge gap and support further research in this area. Because TLR7 is encoded on the X 
chromosome (Christensen et al., 2006), has been associated with sex-specific immune responses to 
viruses (Heil et al., 2004; Souyris et al., 2018) and autoimmune diseases (Christensen et al., 2006; Deane 
et al., 2007), I hypothesized that deletion of TLR7 will improve the outcome of IAV infection in 
females to a greater extent than males. The second part of my project will explore sex differences in 
response to IAV vaccination a subsequent challenge. Because females have higher antibody responses, 
including IgG and respective isotypes than males, which may be mediated by signaling through TLR7 
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in B cells, I hypothesize that deletion of TLR7 will reduce antibody responses and the efficacy of the 







All animal procedures were approved by the Johns Hopkins University Animal Care and Use 
Committee under animal protocol M015H236. 
Mice. 
Adult (age, 7 to 8 weeks) male and female C57BL/6NJ mice were obtained from Jackson Laboratory. 
Before handling, animals were kept in the facility for at least 1 week to acclimate. Tlr7-/- and Tlr7-/y 
mice (B6.129S1Tlr7tm1Flv/J) on C57BL/6NJ background were a gift from Dr. Patricia Gearhart 
(National Institute of Aging) and bred at the Johns Hopkins Bloomberg School of Public Health. All 
animals were housed at up to 5 mice per microisolator cage under standard biosafety level 2 housing 
conditions, with food and water provided ad libitum. Mice were identified via ear punch.  
Influenza A viruses and vaccine. 
Mouse-adapted influenza A virus A/California/04/09 (ma2009; H1N1) generated by Dr. Andrew 
Pekosz from a published sequence (Ye et al., 2010) was used for virus infection. A mouse-adapted 
A/California/04/09 drift variant virus (ma2009dv; H1N1) containing the K166Q mutation of the HA 
sequence was generated by Dr. Ashley Fink in our lab by reverse genetics and used for virus challenge. 
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Infectious virus titers of both viruses were determined using the 50% tissue culture infective dose 
(TCID50) assay.  
The inactivated vaccine was generated by Dr. Ashley Fink and Tanvi Potluri in our lab by 
infecting MDCK cells at an MOI of 0.01 and collecting the infected cell supernatant at 72 hours post-
infection. The infected cell supernatants were centrifuged at 500xg for 10 min and the virus containing 
supernatant was collected. The virus containing supernatant was inactivated by adding 0.05% β-
propiolactone at 4oC overnight followed by incubation at 37oC for 2 h to allow the β-propiolactone to 
break down into non-toxic byproducts (Schaecher, Mackenzie, & Pekosz, 2007). The inactivated virion 
byproducts were purified by ultracentrifugation over a 20% sucrose cushion in a Beckman SW28TI 
rotor at 26,000rpm for 1 h at 4oC. The purified virus containing pellet was then resuspended in 1XPBS 
and a BCA assay (Pierce) was used to quantify protein concentration. Virus inactivation was confirmed 
following virus inactivation and virus purification by performing a TCID50 assay.  
Experimental protocols. 
1. Infection/Pathogenesis 
Adult (7-18 weeks old) male C57BL/6NJ and TLR7-/y mice weighing 25.2 ± 2.3 g and female 
C57BL/6NJ and TLR7-/- mice weighing 19.5 ± 1.3 g were anesthetized with a ketamine (80 
mg/kg) and xylazine (8 mg/kg) cocktail and inoculated intranasally with 30 µL of a low dose 
of the ma2009 IAV (0.04 50% mouse lethal dose [MLD50]). Body mass, rectal temperature, 
and mortality were monitored for 21 days or animals were euthanized for tissue collection at 
specified time points post-infection. Mice were euthanized with an intraperitoneal (ip) 
overdose of ketamine-xylazine. Tissues were collected at 0, 3, 5, or 9 days post-infection for 
virus titration and histopathology. Tissues collected for virus titration were snap frozen, stored 
at -80°C until processing, and then homogenized in .5 mL of DMEM. Homogenized samples 





Adult (7-12 weeks old) male C57BL/6NJ and Tlr7-/y mice weighing 24.6 ± 1.5 g and female 
C57BL/6NJ and Tlr7-/- mice weighing 19.1 ± 2.0 g were vaccinated intramuscularly (i.m.) in 
the hind leg with 20 µg inactivated virus in 40 µL PBS at day 0 and boosted with the same 
dose, 20 µg inactivated virus in 40 µL PBS at day 21(Bodewes et al., 2010; Budimir, de Haan, 
Meijerhof, Gostick, et al., 2013; Budimir, de Haan, Meijerhof, Waijer, et al., 2013; Geeraedts 
et al., 2008). Serum samples were collected by non-terminal submandibular blood sampling 
using the 5 mm Golden Rod at 14 days, 28 days, and 35 days post-vaccination to measure 
antibody and neutralizing antibody titers. Vaccination was confirmed by performing an anti-
IAV IgG ELISA assay using serum collected at 14 days to ensure the highest serum dilution 
OD value was above the average OD of the negative controls; all mice met these criteria.  
At 42 weeks post-vaccination, mice were anesthetized with a ketamine (80 mg/kg) and 
xylazine (8 mg/kg) cocktail and inoculated intranasally with 30 µL of a lethal dose of ma2009dv 
(32 MLD50s). Body mass, rectal temperature, and mortality were monitored for 21 days or 
animals were euthanized for tissue collection at specified time points post-lethal challenge. 
Mice were euthanized by cervical dislocation after administering an intraperitoneal (ip) 
overdose of ketamine-xylazine. Tissues were collected at 1, 3, or 5 days post-challenge for 
virus titration and histopathology. Tissues collected for virus titration were snap frozen, stored 
at -80°C until processing, and then homogenized in .5 mL of DMEM. Homogenized samples 
were centrifuged, and supernatants were collected and stored at -80°C. 
Histology   
The right lungs from euthanized mice were inflated at constant pressure, fixed in Z-fix fixative 
(Anatech) for at least 48 h, embedded in paraffin, cut into 5-µm sections, and mounted on glass slides. 
Tissue sections were stained with hematoxylin and eosin (H&E) and used to evaluated lung 
inflammation. Histopathological scoring for lungs post-infection was performed by single veterinary 
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pathologist blind to the experimental groups. Histopathological scoring for lungs post-challenge was 
performed by a single graduate researcher blind to the experimental groups under the supervision of a 
veterinary pathologist. Three representative sections of each lung were scored and then the three scores 
were averaged. Scores were given for vascular inflammation, bronchial inflammation, and edema on a 
scale ranging from 0 to 3 (1-mild, 2-moderate, 3-severe) with 0.5 increments.  
Virus titration 
MDCK cells were plated in 96-well plates, grown to confluence, and infected with serial 10-fold 
dilutions of lung homogenates in infection media in replicates of 6. The cells were incubated for 6 days 
at 32°C, stained with naphthol blue black (Sigma-Alderich) and cytopathic effect (CPE) was scored 
visually. The Reed-Muench method was used to calculate the tissue culture infectious dose that caused 
CPE in 50% of a monolayer of MDCK cells (TCID50). 
Virus neutralization assay 
Serially diluted serum was mixed with 100 TCID50s of virus (ma2009 IAV) for 1 h at room temperature 
and used to infect quadruplicate wells of confluent MDCK cells for 24 h at 37°C. After incubating for 
16 to 18 h, the inoculum was removed, the cells were washed 1 x with PBS (with calcium and 
magnesium), and fresh medium was added. Next the cells were incubated for 6 days at 32°C and then 
fixed with 4% formaldehyde. CPE was scored following staining with naphthol blue black. The titer 
was calculated as the highest serum dilution that eliminated virus CPE in 2 out of 4 wells per dilution. 
A sample was considered below the limits of detection if there was no neutralization at the 1:4 dilution 
of serum. 
Antibody Enzyme-linked immunosorbent assays (ELISAs) 
Enzyme-linked immunosorbent assay (ELISA) plates (Microlon 96-well high binding plates; Greiner 
Bio-One) were coated with 100 ng of purified virus overnight at 4°C in carbonate puffer (pH 9.6). The 
plates were washed 4 times with PBST (1 x PBS plus 0.1% Tween 20 [Sigma]) and blocked for at least 
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1 h at 37°C with 10% dry milk powder in 1 x PBST. The plates were washed 4 times and serially diluted 
serum with a starting dilution of 1:500 was added to the plates for 1 h at 37°C. Anti-mouse horseradish 
peroxidase (HRP) conjugated secondary IgG (1:250, Thermo), anti-mouse HRP IgG2c (1:20,000, 
Thermo), or anti-mouse HRP IgG1 (1:6,000, Thermo) was added, and the plates were incubated for 1 
h at 37°C. The plates were washed 4 times with PBST, and the reactions were developed with 3,3’5,5’-
tetramethylbenzidine (TMB; BD Biosciences) and stopped using 1 N hydrochloric acid (HCl). The 
absorbance at 450 nm of the plates was read on a plate reader. To determine the sample ELISA titer, 
a cutoff value was obtained by multiplying the average optical density (OD) values for the negative 
controls at each dilution by 3. The titer of the sample was calculated as the highest serum dilution with 
an OD value above the cutoff.  
Influenza antibody avidity index 
ELISA plates were coated with 100 ng of purified virus (as described above) overnight at 4°C in 
carbonate puffer (pH 9.6). The plates were washed 4 times with PBST and blocked for at least 1 h at 
37°C with 10% dry milk powder in 1 x PBST. The plates were washed 4 times again and serum samples 
were added to the wells at a 1:60 dilution for 1 h at 37°C.  To measure antibody avidity, 4M ammonium 
thiocyanate (NH4SCN, Sigma) or 1XPBS was added to the plates for exactly 15 minutes at room 
temperature. The pates were washed 8 times with PBST and anti-mouse HRP conjugated secondary 
IgG (1:250, Thermo) was added for 1 h at 37oC. The plates were washed 4 times with PBST, and the 
reactions were developed with 3,3’5,5’-tetramethylbenzidine (TMB; BD Biosciences) and stopped 
using 1 N hydrochloric acid (HCl). The absorbance at 450 nm of the plates was read on a plate reader. 
The antibody avidity index was determined by normalizing the NH4SCN treated absorbance values to 
the corresponding 1XPBS (untreated) values for each sample in duplicate.  
Statistical analyses 
Morbidity data was analyzed with a one-way ANOVA followed by Tukey post-hoc testing using the 
greatest body mass loss observed over the entire time-period as the dependent variable. Antibody titers, 
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virus titers, and histopathological data were analyzed using one-way ANOVA followed by Tukey post-
hoc testing. Mean differences were considered statistically significant if p was <0.05. Graphs were 







The absence of TLR7 does not alter sex differences in outcome of influenza infection 
We first examined the contribution of TLR7 signaling pathways to sex differences in host defense 
following IAV infection. Prior studies conducted in our lab have demonstrated that IAV infection 
results in greater body mass loss, used as a surrogate measure of clinical disease, among female 
C57BL/6CR mice as compared to males (Robinson et al., 2011). To test whether the absence of TLR7-
dependent pathways modifies these sex differences in influenza-induced morbidity, we infected wild-
type (WT) and Tlr7 deficient mice intranasally (i.n.) with a sublethal dose of ma2009 IAV and analyzed 
body mass loss over 20 days following inoculation (Figure 1A). A one-way ANOVA was conducted to 
determine if body mass loss was different for male and female mice in the presence and absence of 
Tlr7. Mice were classified into four groups: WT males (n=5), Tlr7-/y males (n=9), WT females (n=5), 
and Tlr7-/- females (n=7) and data was collected from two independent experiments. There was a 
statistically significant difference between groups as determined by one-way ANOVA (F(3,22)=11.70, 
p=.0001). As expected, a Tukey post-hoc test revealed that body mass loss was statistically greater in 
female WT mice as compared to male WT mice (-11.3 ± 3.3 % body mass loss, p=.011) (Figure 1B). 
Surprisingly, female Tlr7-/- mice also lost significantly greater body mass loss as compared to male Tlr7-
/y mice (-12.4 ± 2.6% body mass loss, p<0.001) and there was no statistically significant differences 
between male WT mice and male Tlr7-/y mice (.88 ± 2.9% body mass loss, p=0.99), or female WT mice 
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and female Tlr7-/- mice (-.24 ± 3.0% body mass loss, p=1.0).  Thus, the absence of TLR7 did not 
significantly affect sex differences in body mass loss following IAV infection.  
To further investigate the role of TLR7-mediated host defense pathways in protecting male 
and female mice over the course of a sub-lethal IAV infection, we collected and analyzed lung samples 
from infected mice at 0, 3, 5, and 9 days post-inoculation (Figure 1A). A one-way ANOVA was 
conducted to determine if viral titers were different for male and female mice in the presence and 
absence of TLR7 at 3, 5, and 9 days post-inoculation (dpi). Mice were again classified into four groups 
for each day: WT males (3 dpi n=5, 5 dpi n=5, 9 dpi n=10), Tlr7-/y males (3 dpi n=9, 5 dpi n=5, 9 dpi 
n=11), WT females (3 dpi n=5, 5 dpi n=5, 9 dpi n=10), and Tlr7-/- females (3 dpi n=5, 5 dpi n=5, 9 
dpi n=9) and data was collected from 4 independent experiments.. There was no statistically significant 
difference between groups as determined by a one-way ANOVA at 3 dpi (F(3,20)=0.71, p=.56) or 5 
dpi (F(3,16)=1.24, p=.33), but there was a statistically significant difference at 9 dpi (F(3,36)=6.78, 
p=0.001) (Figure 1C). Tukey post-hoc test at 3, 5, and 9 dpi revealed that the average viral titer was 
statistically lower in female WT mice than male WT mice at 9 dpi (-1.46 ± .40 log10 TCID50/mL, 
p=0.003). In contrast there was no statistically significant difference between the mean viral titer of 
Tlr7 deficient female and male mice at 9 dpi (-.42 ± .40 log10 TCID50/mL, p=.71). Furthermore, there 
was no statistically significant difference in the mean viral titers of females in the presence or absence 
of TLR7 at 9 dpi (.99 ± .41 log10 TCID50/mL, p=.081), while male Tlr7 deficient mice had statistically 
significant lower viral titers than male WT mice (-2.01 ± .39 log10 TCID50/mL, p<0.001). Therefore, 
sex differences in viral titers observed among WT mice were eliminated as a result of Tlr7 deficiency 
in male mice.  
The reduction in viral titers observed in male Tlr7-/y mice could possibly be explained by 
increased inflammatory responses in the lung, we therefore examined pulmonary inflammation in 
tissue sections of the lungs collected at 3, 5, and 9 dpi. Male and female mice deficient in Tlr7 on 
average showed similar levels of pulmonary inflammation as WT mice, with no significant difference 
in the average cumulative inflammation score between any of the treatment groups as determined by 
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a one-way ANOVA at 3 dpi (F(3,13)=0.65, p=.60), 5 dpi (F(3,16)=2.12, p=.14), and 9 dpi 
(F(3,16)=0.74, p=0.54) (Figure 1D).  
TLR7 mediates sex differences in quantity and quality of antibodies produced following 
influenza vaccination 
We next examined the contribution of TLR7-dependent signaling to sex differences in response to 
vaccination. Tlr7 is expressed in B cells which are responsible for producing antibodies that establish 
long-lived adaptive immunity and protection. To better understand the possible role of TLR7-
dependent signaling in antibody production following vaccination, we collected serum and measured 
anti-IAV antibody responses at 28 and 35 days post-vaccination (dpv) (Figure 2A). A one-way 
ANOVA was conducted to determine if antibody titers were different for male and female mice in the 
presence and absence of TLR7 at 28 and 35 dpv. Mice were again classified into four groups for each 
day: WT males (28 and 35 dpv n=14), Tlr7-/y males (28 and 35 dpv n=14), WT females (28 and 35 dpv 
n=14), and Tlr7-/- females (28 and 35 dpv n=11), and data was collected from 3 independent 
experiments. There was a statistically significant difference between the average anti-IAV IgG titer of 
the treatments groups at 28 dpv (F(3,49)=7.58, p<.001) and at 35 dpv (F(3,49)=4.88, p=.0048). Tukey 
post-hoc testing at 28 and 35 dpv revealed that the average anti-IAV IgG titer of WT females was 
significantly higher than WT males at 35 dpv (-154,500 ± 42,522, p=.0025), but there was no 
statistically significant difference at 28 dpv (-97,429 ± 42,522, p=.11)  (Figure 2B). In contrast, female 
Tlr7 deficient mice mounted similar anti-IAV IgG titers as male Tlr7 deficient mice with no statistically 
significant difference in the average anti-IAV IgG titers at 28 dpv (-13,737± 45,328, p=.99) and 35 dpv 
(-8,185 ± 45,328, p=1.0). Additionally, female WT mice on average had significantly higher anti-IAV 
IgG titers than female Tlr7 deficient mice at 35 dpv (-178,351± 45,328, p<.001), but not at 28 dpv (-
98,156 ± 45,328, p=.14). Male WT mice on average had similar anti-IAV IgG titers as male Tlr7 
deficient mice at 28 dpv (14,464 ± 42,522, p=.99), and 35 dpv (-32036 ± 42,522, p=.88). 
19 
 
The lack of sex differences in anti-IAV IgG titers among Tlr7 deficient mice does not rule out 
sex differences in the ability of antibodies to bind or neutralize virus particles. To exclude the possibility 
of compensatory sex differences in antibody quality, we analyzed immune sera at 28 and 35 dpv using 
neutralization (Figure 2C) and avidity (Figure 2D) assays. Data was collected from 3 independent 
experiments. A one-way ANOVA analysis was conducted to determine if mean neutralizing antibody 
titers and mean antibody avidity indices were different among the four treatment groups at 28 and 35 
dpv. There were significant differences in the average neutralizing antibody titers at 28 dpv 
(F(3,49)=5.63, p=0.002) and 35 dpv (F(3,49)=3.25, p=0.029) (Figure 2C). Additionally there were 
significant differences in the average antibody avidity index at 35 dpv (F(3,48)=13.31, p=<.001) (Figure 
2D). Tukey post-hoc testing at 28 and 35 dpv revealed that on average female WT mice had anti-IAV 
neutralizing antibody titers significantly higher than male WT mice at 28 dpv (-3,500 ± 962.1, 
p=0.0025) and antibody avidity indices significantly higher than that of male WT mice at 35 dpv (-.16 
± 0.048, p=0.007). Among Tlr7 deficient mice there was no sex difference in average anti-IAV 
neutralizing antibody titer at 28 dpv (-226.7 ± 982.6, p=1.0) or avidity at 35 dpv (-.77 ± .047, p=.37).  
Furthermore, female WT mice on average had anti-IAV neutralizing antibody significantly greater than 
female Tlr7 deficient mice at 28 dpv (3810 ± 999.9, p=.0014) and greater avidity indices than female 
Tlr7 deficient mice at 35 dpv (.21 ± .049, p<0.001). In contrast male WT mice on average had similar 
anti-IAV neutralizing titers to male Tlr7 deficient mice at 28 dpv (537 ± 944.1, p=.94), but avidity 
indexes that were on average significantly higher than male Tlr7 deficient mice at 35 dpv (0.13 ± .046 
, p=.038) (Figure 2C, D).    
IgG isotype switching to IgG2a/c has been shown to play a critical role in influenza vaccine 
efficacy and protection (Baldridge & Buchmeier, 1992; Coutelier, 1987; Heer et al., 2007; Kaminski et 
al., 1986) and previous studies suggest that TLR7 may play a role in this process (Heer et al., 2007; 
Jeisy-Scott et al., 2012). To further detail possible sex differences caused by TLR7-depedent signaling 
in the antibody response to vaccination, we examined isotype switching in immune sera at 35 dpv. This 
timepoint was chosen due to statistically significant sex differences observed in anti-IAV IgG titer 
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among WT mice. Data was collected from 2 independent experiments. One-way ANOVA analysis of 
isotypes revealed that at 35 dpv the anti-IAV IgG2c antibody titers are significantly different among 
the four treatment groups (F(3,30)=16.76, p<0.001). Tukey post-hoc analysis revelated that female WT 
mice on average had significantly higher anti-IAV IgG2c antibody titers than male WT mice (-150,056 
± 48,083 , p=.020), while female Tlr7 deficient mice had comparable IgG2c antibody titers as male Tlr7 
deficient mice (-833.3 ± 48,083, p>.99) (Figure 2E). At the same time point, anti-IAV IgG1 antibody 
titers did not differ between the four treatment groups (F(3,29)=2.20, p=0.11) (Figure 2F). However, 
consistent with prior studies (Heer et al., 2007) male and female Tlr7 deficient mice together had 
significantly different IgG1 titers than male and female WT mice(F(1,31)=8.66, p=0.006). On average 
Tlr7 deficient mice had IgG1 titers significantly greater than WT mice (8923.7 ± 3032, p=0.006). 
Together these results suggest that in female mice, TLR7-dependent signaling has an important role in 
the production IgG2c antibodies and neutralizing antibodies with high avidity.  
Tlr7 deficiency eliminates sex differences in protection following challenge with an IAV drift 
variant virus 
Having demonstrated that female Tlr7 deficient mice generate lower vaccine-induced antibody titers 
and lower quality antibody following vaccination than female WT mice, which eliminates sex 
differences in antibody responses, we then examined whether Tlr7 deficiency also eliminates sex 
differences in vaccine-induced protection following challenge. Previous studies conducted in our lab 
have shown that vaccinated female WT mice are better protected following challenge with a drift-
variant virus, losing less weight than vaccinated male mice (Dr. Ashley Fink, unpublished data). To 
evaluate the possible role of TLR7-dependent signaling in vaccine-induced protection, we compared 
body mass loss, a surrogate measure of clinical disease, of vaccinated male and female mice in the 
presence and absence of Tlr7 following a lethal challenge with ma2009dv IAV (Figure 3A). One-way 
ANOVA analyses were conducted to determine if average percent body mass loss was different for 
male and female mice in the presence and absence of Tlr7. Mice were classified into four groups: WT 
males (n=9), Tlr7-/y males (n=9), WT females (n=8), and Tlr7-/- females (n=8) and data was collected 
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from 2 independent experiments. As expected, average percent weight loss was significantly different 
among all four groups (F(3,30)=9.14, p<0.001). Furthermore, Tukey post-hoc testing revealed that 
vaccinated male WT mice on average lost more body mass than vaccinated female WT mice, however 
this difference was not statistically significant (1.59 ± .92 % body mass loss, p=.33) (Figure 3B). 
Vaccinated male Tlr7 deficient mice on average lost significantly more body mass than vaccinated 
female Tlr7 deficient mice (2.57 ± .92 % body mass loss, p=.04). This was surprising because no sex 
differences were observed in the quantity or quality of anti-IAV antibody produced prior to challenge. 
Additionally, vaccinated male Tlr7 deficient mice on average lost significantly more body mass than 
vaccinated male WT mice (-3.10 ± .89 % body mass loss, p<.01) and female Tlr7 deficient on average 
lost more body mass than vaccinated female WT mice, however the difference between female mice 
was not significant (-2.12 ± .95 % body mass loss, p=.14). 
To further detail the possible role of TLR7-dependent signaling in vaccine-induced protection 
against IAV, we next assessed the host’s ability to clear virus from the lungs. This is the most important 
parameter for vaccine efficacy. To measure viral clearance, we collected lung samples from vaccinated 
mice at 1, 3, and 5 days post-challenge (dpc) and analyzed viral load (Figure 3A). Mice were again 
classified into four groups for each day: WT males (1 dpc n=9, 3 dpc n=10, 5 dpc n=10), Tlr7-/y males 
(1 dpc n=10, 3 dpc n=10, 5 dpc n=13), WT females (1 dpc n=10, 3 dpc n=9, 5 dpc n=10), and Tlr7-
/- females (1 dpc n=8, 3 dpc n=9, 5 dpc n=9) and data was collected from 6 independent experiments. 
A one-way ANOVA analysis was used to determine if there were significant differences in the mean 
viral titer of the four treatment groups at 1, 3, and 5 dpc. Significant differences were found in average 
viral titer at 1 dpc (F(3,33)=3.38, p<0.05), 3 dpc (F(3,34)=3.48, p<0.05), and 5 dpc (F(3,38)=22.15, 
p<0.001). As seen previously in our lab (Dr. Ashley Fink, data unpublished), Tukey post-hoc testing 
revealed the average viral titer was significantly lower in vaccinated female WT mice as compared to 
vaccinated male WT mice at 3 dpc (-1.39 ± 0.57 log10 TCID50/mL, p<0.05) and 5 dpc (-1.03 ± 0.42 
log10 TCID50/mL, p<0.05). In contrast, vaccinated female Tlr7 deficient mice had viral titers 
comparable to vaccinated male Tlr7 deficient mice at 3 dpc (-1.40 ± .71 log10 TCID50/mL, p=0.06) and 
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5 dpc (-1.01 ± 0.53 log10 TCID50/mL, p=0.083). Additionally, vaccinated male Tlr7 deficient mice on 
average had similar viral titers to vaccinated male WT mice at 3 dpc (0.52 ± 0.71 log10 TCID50/mL, 
p<0.47) and significantly higher viral titers than vaccinated male WT mice at 5 dpc (2.29 ± 0.47 log10 
TCID50/mL, p<0.001). Female Tlr7 deficient also on average had similar viral titers to vaccinated 
female WT mice at 3 dpc (0.51 ± 0.57 log10 TCID50/mL, p=0.39), and significantly higher viral titers 
than vaccinated female WT mice at 5 dpc (2.31 ± 0.48 log10 TCID50/mL, p<0.05). Together these data 
suggest that female mice are better protected by vaccines than male mice and this protection is 



























































































Figure 1. Toll-like receptor 7 did not affect sex differences in clinical disease following
influenza infection. (A) Infection scheme. C57BL/6NJ mice were inoculated intranasally (i.n.) with
mouse-adapted (ma) 2009 H1N1 influenza A virus. (B) Following infection, body weight was recorded
daily as a surrogate measure of morbidity. Body mass loss curve shows results of n=5-9 from two
independent infection experiments. (C) The viral load in lung tissue was determined from lungs collected at
3, 5, and 9 days post-inoculation (dpi) by TCID50 assay. Results are presented from 4 independent
experiments with n=5-11/treatment group/time point. (D) Inflammation in lung tissue collected at 3, 5,
and 9 dpi was quantified based on a 0-3 scale of perivascular, peribronchiolar and alveolar inflammation.
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Figure 2. Sex differences in antibody titers and quality are eliminated in the absence of
TLR7. (A) Vaccination and challenge scheme. C57BL6/NJ mice (n=7-14/treatment group) were
vaccinated intramuscularly (i.m.) with 20g inactivated mouse-adapted (ma) influenza A virus (H1N1) in
40 L PBS and boosted with the same dose at 21 days post-vaccination  (dpv). (B) Serum IgG antibody
titers were measured at 28 and 35 dpv by  ELISA assay. (C) Serum neutralizing antibody titers were
measured at 28 and 35 dpv by neutralizing antibody assay. (D) Serum IgG antibody avidity was measured
at 35 dpv by avidity ELISA assay. (E) Serum IgG2c antibody titers were measured at 35 dpv by ELISA







































































Figure 3. Tlr7 deficiency eliminates sex differences in protection following challenge with an IAV drift
variant virus. (A) Vaccination and challenge scheme. C57BL6/NJ mice (n=7-13/treatment group) were vaccinated
intramuscularly (i.m.) with 20g inactivated mouse-adapted (ma) influenza A virus (H1N1) in 40 L PBS and boosted
with the same dose at 21 days post-vaccination  (dpv). At 42 dpv, vaccinated mice were challenged intranasally  (i.n.)
with a lethal dose of ma2009 drift variant virus. (B) Following challenge, body weight was recorded daily as a surrogate
measure of morbitity. Weight loss curve shows results of n=7-10 from two independent experiments. (C) The viral load
in lung tissue was determined from lungs collected at 1, 3, and 5 days post-challenge  (dpc) by TCID50 assay. * = p <





Several studies of humans and mice have shown that the severity of influenza virus infection and the 
efficacy of influenza virus vaccination significantly differs between males and females. Despite 
increasing evidence that TLR7, one of the PRRs that detects influenza viruses, escapes XIC in a 
significant proportion of female immune cells (Souyris et al., 2018), it’s role in mediating sex differences 
in influenza infection and vaccine has not been studied. In the present study, we investigated the effects 
of TLR7-dependent signaling on sex differences in influenza pathogenesis, influenza vaccine response, 
and influenza vaccine-induced protection. We found that in C57NL/6NJ mice, TLR7-dependent 
signaling independently mediates sex differences in the antibody response to influenza vaccine and 
vaccine-induced protection but does not independently mediate sex differences in influenza related 
morbidity following infection of naïve mice. Following influenza vaccination, female mice produced 
higher antibody titers than males, but only in the presence of TLR7-dependent signaling. Decreased 
antibody titers following vaccination significantly affected the vaccine-induced protection of female 
Tlr7-/- mice upon challenge by increasing virus titers in the lungs.  
TLR7 is thought to play a differential role during influenza infection versus immunization 
because of the different context in which viral RNA (vRNA) is recognized by PRRs in the two contexts. 
In the context of infection, vRNA can be recognized by a combination of at least three different 
families of PRRs over the course of IAV’s life cycle in late endosomes or the cytosol, RIG-I, TLRs, 
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and NLRP3 (Ichinohe, Lee, Ogura, Flavell, & Iwasaki, 2009; Jeisy-Scott et al., 2012). Thus the absence 
of a unique weight-loss phenotype in TLR7 deficient mice in this study could be explained by 
redundancy in TLR7 function or by the sufficiency of multiple PRR pathways in the absence of TLR7 
to facilitate the induction of the adaptive immune response (Jeisy-Scott et al., 2012; Trinchieri & Sher, 
2007). It is of interest to note that sex differences in influenza induced morbidity were maintained even 
in the absence of TLR7, suggesting that either redundant PRRs or the combination of PRR pathways 
activated during influenza infection act in a sex-specific manner.  
While there was no unique weight loss phenotype in TLR7 deficient mice following influenza 
infection, there were significant sex differences in the control of infectious viral titer. In this study, the 
absence of TLR7-dependent signaling in male mice, but not female mice, was associated with lower 
viral titers at 9 dpi. Decreased viral titers in Tlr7 deficient mice have been found in previous studies as 
measured by nucleoprotein RNA-copies via qRT-PCR following infection with a more virulent IAV 
strain and in a study of mice also deficient in mitochondrial antiviral signaling (MAVS), part of the 
RIG-I pathway (Pang et al., 2013; Stegemann-Koniszewski et al., 2016). This finding is also consistent 
with other studies of knockout mice lacking a single TLR, which in most cases have either normal 
control of infection or more resistance to infection than knockout mice lacking an adaptor protein 
such as MyD88 (Akira, Uematsu, & Takeuchi, 2006; Fritz & Girardin, 2005; Trinchieri & Sher, 2007). 
Importantly, findings from this study make the novel contribution that TLR7-depedent signaling may 
play a sex-specific role in regulating viral replication in males. However, further investigation of sex 
differences in the activation of cytotoxic T cells which are associated with viral clearance and the role 
of sex hormones could provide more insight into the biological mechanism behind these findings. 
Alternatively to influenza infection, in the context of immunization with an inactivated 
influenza vaccine, the inactivated viral particles are primarily recognized through the cell-intrinsic 
endocytic pathway by TLR7 (Jeisy-Scott et al., 2012). Therefore, endosomal TLR7 plays a critical role 
in activating the immune response during vaccination. Our findings support previous work which has 
shown that TLR7-dependent signaling in B cells is important for the induction of appropriate anti-
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influenza humoral responses following vaccination with TLR7 deficient mice having increased IgG1 
antibody and decreased IgG2c antibody titers (Heer et al., 2007; Jeisy-Scott et al., 2012). Furthermore, 
this study shows that TLR7-depedent signaling mediates sex differences in the quality of anti-influenza 
humoral response of C57BL/6NJ mice following influenza vaccination. Detailed analyses of the 
efficacy of different antibody isotypes have identified IgG2c as the key isotype for anti-influenza 
antibody-mediated effector functions in C57BL/6 mice (Baldridge & Buchmeier, 1992; Coutelier, 
1987; Heer et al., 2007; Kaminski et al., 1986). Our findings, consistent with prior research conducted 
in our lab, show that female mice have higher IG2c antibody titers than male mice in response to 
influenza vaccination and these sex differences are eliminated in the absence of TLR7-dependent 
signaling; however, IgG1 antibody titers did not differ by sex in either treatment group. We also found 
that the absence of TLR7-depedent signaling eliminated sex differences in the avidity and neutralization 
potential of antibodies generated in response to vaccination.  
Given the role of IgG2c antibodies in vaccine efficacy and the lack of sex differences observed 
in IgG2c antibody titer in Tlr7 deficient mice, we hypothesized that male and female mice would be 
equally unprotected when challenged with a lethal dose of a ma2009dv IAV following vaccination. To 
our surprise female mice lost less body mass following a lethal challenge than male mice in the absence 
of TLR7-depedent signaling. Whereas male Tlr7-/y mice lost significantly more weight than male WT 
mice, female Tlr7-/- mice lost comparable amount of body weight to their WT counterpart. More 
importantly, differences in viral titer following challenge closely matched trends in antibody titer. There 
was a significant difference between female Tlr7-/- mice and female WT mice in viral titer at 5 dpc and 
no sex difference between Tlr7 deficient mice at the same time point, as also seen in antibody titers 
following vaccination.  
This study shows that TLR7-depedent signaling mediates sex differences in the antibody 
response to vaccine and viral clearance upon secondary infection with a drift variant virus. Additionally, 
differences in antibody titers were closely correlated with protection as measured through viral 
clearance following challenge. Persistent sex differences in morbidity following vaccination and 
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challenge in the absence of TLR7-dependent signaling or sex differences in antibody titer, may have 
been due to the robust nature of the female immune response. It is well established that female humans 
and mice have a stronger innate and adaptive immune response. Therefore, it is possible that more 
signaling pathways must be disrupted in order to disrupt body mass loss following lethal challenge in 
females or a decreased amount of antibody is still sufficient to confer protection in females. Deeper 
analysis of the adaptive immune response to vaccination and challenge in Tlr7 deficient males and 
females would reveal sex differences independent of TLR7-depedent signaling. 
From an evolutionary perspective, the ability of females to quickly generate a lot of antibody 
is critical for providing passive immunity to offspring through breastmilk. Newborns leave an almost 
germ-free intrauterine environment to enter a highly contaminated extrauterine state and antibodies in 
breastmilk provide protection from an abundance of potentially pathologic organisms that could lead 
to numerous infectious conditions. Furthermore, there is increasing evidence that antibodies in 
breastmilk may also play an important role in the development of the infant’s microbiome and intestinal 
immune homeostasis (Walker & Iyengar, 2015). TLR7 may escape XIC in females to allow mothers to 
generate sufficient antibodies in breastmilk to protect their offspring from deadly pathogens. This 
would explain why females have the ability to produce more antibodies in the more modern context 
of vaccination. Interestingly B cell activating factor (BAFF) which is present in human breastmilk was 
recently shown to augment IgA2 production in TLR7 stimulated B cells isolated from human blood 
samples, however more data is needed to warrant further investigation of this hypothesis (den Hartog 
et al., 2018). 
In summary, this study provides new evidence that TLR7-depedent signaling mediates sex 
differences in the production of antibodies following influenza vaccination and viral clearance 
following subsequent challenge. Future studies should investigate sex differences in different cell 
populations activated following vaccination to better understand how Tlr7 mediates better protection 
in females following challenge. Additionally, these data support further investigation of the sex specific 
effects of using TLR7 adjuvants in vaccines which may only be effective for improving vaccine efficacy 
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